Dietary quality using four dietary indices and lung cancer risk: the Golestan Cohort Study (GCS) von Wang, Qian, Hashemian, Maryam, Sepanlou, Sadaf G., Sharafkhah, Maryam, Poustchi, Hossein, Khoshnia, Masoud, Gharavi, Abdolsamad, Pourshams, Akram, Malekshah, Akbar Fazeltabar, Kamangar, Farin, Etemadi, Arash, Abnet, Christian C., Dawsey, Sanford M., Malekzadeh, Reza, Boffetta, Paolo

Volltext

One-carbon metabolism biomarkers and upper gastrointestinal cancer in the Golestan Cohort Study von Inoue-Choi, Maki, Freedman, Neal D, Etemadi, Arash, Hashemian, Maryam, Brennan, Paul, Roshandel, Gholamreza, Poustchi, Hossein, Boffetta, Paolo, Kamangar, Farin, Amiriani, Taghi, Norouzi, Alireza, Dawsey, Sandy, Malekzadeh, Reza, Abnet, Christian C

Volltext

Abstract 729: Meat consumption and risk of esophageal and gastric cancer in the Golestan Cohort Study von Collatuzzo, Giulia, Etemadi, Arash, Kamangar, Farin, Christian, Abnet, Dawsey, Sandy, Brennan, Paul, Sotoudeh, Masoud, Poutschi, Hossein, Khoshnia, Masoud, Pourshams, Akram, Malekzadeh, Reza, Boffetta, Paolo

Volltext

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma von Hussain, Maha, Daignault, Stephanie, Agarwal, Neeraj, Grivas, Petros D., Siefker‐Radtke, Arlene O., Puzanov, Igor, MacVicar, Gary R., Levine, Ellis Glenn, Srinivas, Sandy, Twardowski, Przemyslaw, Eisenberger, Mario A., Quinn, David I., Vaishampayan, Ulka N., Yu, Evan Y., Dawsey, Scott, Day, Kathleen C., Day, Mark L., Al‐Hawary, Mahmoud, Smith, David C.

Volltext

Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma von Makrakis, Dimitrios, Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Lin, Genevieve Ihsiu, Diamantopoulos, Leonidas N., Jindal, Tanya, Vather-Wu, Naomi, Zakharia, Yousef, Tripathi, Nishita, Agarwal, Neeraj, Dawsey, Scott, Gupta, Shilpa, Lu, Eric, Drakaki, Alexandra, Liu, Sandy, Zakopoulou, Roubini, Bamias, Aristotelis, Fulgenzi, Claudia-Maria, Cortellini, Alessio, Pinato, David, Barata, Pedro, Grivas, Petros, Khaki, Ali Raza, Koshkin, Vadim S.

Volltext

Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma von Makrakis, Dimitrios, Talukder, Rafee, Lin, Genevieve Ihsiu, Diamantopoulos, Leonidas N., Dawsey, Scott, Gupta, Shilpa, Carril-Ajuria, Lucia, Castellano, Daniel, de Kouchkovsky, Ivan, Koshkin, Vadim S., Park, Joseph J., Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler F., McKay, Rana R., Tripathi, Nishita, Agarwal, Neeraj, Vather-Wu, Naomi, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael E., Cortellini, Alessio, Maria, Fulgenzi Claudia Angela, Pinato, David J., Nelson, Ariel, Hoimes, Christopher J., Gupta, Kavita, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Murgic, Jure, Fröbe, Ana, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Lu, Eric, Kumar, Vivek, Lorenzo, Giuseppe Di, Joshi, Monika, Isaacsson-Velho, Pedro, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Jang, Albert, Barata, Pedro, Sonpavde, Guru, Yu, Evan Y., Montgomery, Robert Bruce, Grivas, Petros, Khaki, Ali Raza

Volltext

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma von Talukder, Rafee, Makrakis, Dimitrios, Lin, Genevieve Ihsiu, Diamantopoulos, Leonidas N., Dawsey, Scott, Gupta, Shilpa, Carril-Ajuria, Lucia, Castellano, Daniel, de Kouchkovsky, Ivan, Jindal, Tanya, Koshkin, Vadim S., Park, Joseph J., Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler F., McKay, Rana R., Tripathi, Nishita, Agarwal, Neeraj, Vather-Wu, Naomi, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael E., Cortellini, Alessio, Fulgenzi, Claudia Angela Maria, Pinato, David J., Nelson, Ariel, Hoimes, Christopher J., Gupta, Kavita, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Murgic, Jure, Fröbe, Ana, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Lu, Eric, Kumar, Vivek, Lorenzo, Giuseppe Di, Joshi, Monika, Isaacsson-Velho, Pedro, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Sonpavde, Guru, Wright, Jonathan L., Yu, Evan Y., Montgomery, Robert Bruce, Hsieh, Andrew C., Grivas, Petros, Khaki, Ali Raza

Volltext

Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC) von Grivas, Petros, Agarwal, Neeraj, Siefker-Radtke, Arlene O., Daignault, Stephanie, Puzanov, Igor, MacVicar, Gary R., Levine, Ellis Glenn, Srinivas, Sandy, Twardowski, Przemyslaw, Eisenberger, Mario A., Quinn, David I., Vaishampayan, Ulka N., Yu, Evan Y., Dawsey, Scott, Day, Kathleen C., Day, Mark L., Smith, David C., Hussain, Maha

Volltext